Background: Relative vaccine effectiveness (rVE) are metrics commonly reported to compare absolute VE (aVE) of 2 vaccine products.
Methods: Estimates of rVE for enhanced influenza vaccines (eIV) vs standard inactivated influenza vaccine (IIV) have been assessed across different seasons, influenza-specific endpoints, and nonspecific endpoints (eg, all-cause cardiovascular hospitalizations). To illustrate the challenges of comparability across studies, we conducted a scenario analysis to evaluate the effects of varying absolute VE (aVE) of IIV (ie, as compared with placebo) on the interpretation of rVE of eIV vs IIV.
Results: We show that estimates of rVE might not be comparable across studies because additional benefits commensurate with a given estimate of rVE are dependent on the aVE for the comparator vaccine, which can depend on factors such as host response to vaccine, virus type, and clinical endpoint evaluated.
Conclusions: These findings have implications for interpretation of rVE across studies and for sample size considerations in future trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciab1016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Socioeconomic disparities in influenza vaccination uptake: impact of the COVID-19 pandemic in South Korea.
BMC Public Health
January 2025
International Healthcare Center, Seoul National University Hospital, Seoul, Korea.
Background: This study aimed to investigate the sociodemographic and behavioral factors related to increased influenza vaccination uptake during the COVID-19 pandemic in South Korea, particularly among adults not eligible for free vaccination.
Methods: Analyzing data from 78,815 participants in the Korea National Health and Nutrition Examination Survey (2010-2021), we assessed trends in influenza vaccination coverage. Various sociodemographic factors, behavioral aspects, and psychological stress levels were assessed using multivariable logistic regression to evaluate the difference in vaccination response during pre-/post-COVID-19 periods.
Next-generation vaccines for influenza B virus: advancements and challenges.
Arch Virol
January 2025
CAS Key Laboratory of Molecular Virology & Immunology, Institutional Center for Shared Technologies and Facilities, Pathogen Discovery and Big Data Platform, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Yueyang Road 320, Shanghai, 200031, China.
To battle seasonal outbreaks of influenza B virus infection, which continue to pose a major threat to world health, new and improved vaccines are urgently needed. In this article, we discuss the current state of next-generation influenza B vaccine development, including both advancements and challenges. This review covers the shortcomings of existing influenza vaccines and stresses the need for more-effective and broadly protective vaccines and more-easily scalable manufacturing processes.
View Article and Find Full Text PDFBifurcation analysis of an influenza A (H1N1) model with treatment and vaccination.
PLoS One
January 2025
Department of Mathematics, University of Dhaka, Dhaka, Bangladesh.
This research uses numerical simulations and mathematical theories to simulate and analyze the spread of the influenza virus. The existence, uniqueness, positivity, and boundedness of the solution are established. We investigate the fundamental reproduction number guaranteeing the asymptotic stability of equilibrium points that are endemic and disease-free.
View Article and Find Full Text PDFApnea After 2-Month Vaccinations in Hospitalized Preterm Infants: A Randomized Clinical Trial.
JAMA Pediatr
January 2025
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Importance: Preterm infants are recommended to receive most vaccinations at the same postnatal age as term infants. Studies have inconsistently observed an increased risk for postvaccination apnea in preterm infants.
Objective: To compare the proportions of hospitalized preterm infants with apnea and other adverse events in the 48 hours after 2-month vaccinations vs after no vaccinations.
Design, synthesis and antiviral evaluation of triazole-linked 7-hydroxycoumarin-monoterpene conjugates as inhibitors of RSV replication.
RSC Med Chem
December 2024
Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry 9, Akademika Lavrentieva Ave. 630090 Novosibirsk Russia
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in babies across the world. Irrespective of progress in the development of RSV vaccines, effective small molecule drugs are still not available on the market. Based on our previous data we designed and synthesized triazole-linked coumarin-monoterpene hybrids and showed that they are indeed effective in inhibiting the RSV replication.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!